Short answer
Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Arbutus Biopharma Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 12, 2026
- Exhibit 99.1 contains financial results and additional company information
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $1.0M versus $10.7M, reflecting the absence of a prior-year $9.6M deferred-revenue recognition
- Moderna settlement delivered $178.4M in July, materially strengthening liquidity beyond June 30 cash and securities of $92.6M
- Planned shareholder capital return of up to approximately $230M beginning Q3 2026, subject to board approval
- Pfizer and BioNTech patent lawsuits span 21 countries, creating potential litigation-driven licensing or damages upside
- FDA alignment on imdusiran Phase 2b design reduces regulatory uncertainty, but clinical execution and funding remain key risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arbutus Biopharma Corp 8-K filings
Get the next ABUS 8-K as it lands
Follow ABUS for push alerts, or ask the research agent what this filing means.